Global Health Landscape: Legal Battles, Tariffs, and Innovations

Recent developments in health news include Novo Nordisk filing lawsuits over unauthorized semaglutide sales, Brazilian bird flu impacting global chicken trade, and Novartis eyeing a takeover of Avidity Biosciences. Other highlights are FDA approval of Jazz Pharma's tumor drug, US tariffs on pharma imports, and the dire water crisis in Gaza.

In a significant legal development, Danish pharmaceutical giant Novo Nordisk announced the filing of 14 additional lawsuits in the United States. These lawsuits target companies selling unauthorized versions of semaglutide, a crucial ingredient in its renowned Wegovy and Ozempic drugs.

Meanwhile, the global poultry industry is facing challenges due to an outbreak of bird flu in Brazil. This has led several countries to impose trade restrictions. However, Brazil's declaration of being virus-free after 28 days has seen some importers lifting their bans.

On the financial front, Swiss pharmaceutical company Novartis is reportedly considering a takeover bid for US-based Avidity Biosciences, boosting Avidity's share price. Additionally, the US FDA has approved Jazz Pharmaceuticals' new drug for treating a rare brain tumor, expanding its portfolio.

(With inputs from agencies.)